NeoImmuneTech to Show Significant Advances on NT-I7 (efineptakin alfa) at 2022 ASCO Annual Meeting

Poster discussion will highlight anti-tumor activities of NT-I7 combined with pembrolizumab in heavily pretreated patients for whom checkpoint inhibitors are usually ineffective NeoImmuneTech, Inc. (NIT or “NeoImmuneTech”), a clinical-stage T cell-focused biopharmaceutical company, today announced it will present new clinical data for its lead asset NT-I7 (efineptakin alfa) across three presentations at the American Society of Clinical Oncology (ASCO) annual meeting, to be held in Chicago, June 3-7, 2022 . These include one poster discussion and two poster displays. Dr. Se Hwan Yang, Ph.D., President and Chief Executive Officer of NeoImmuneTech said: “We are pleased that the ASCO Scientific Program Committee selected our abstract on the efficacy and safety of NT-I7 in combination with pembrolizumab for a poster discussion. While the abstract was based on data cutoff as of January 14, 2022, the actual Phase 2a data presented and discussed at the congress will have a few additional months of follow-up. They will shed new light on the benefit of combining NT-I7 with a checkpoint inhibitor (CPI) in patients with immune-cold microsatellite stable colorectal cancer or pancreatic cancer and in those who progressed on previous CPI treatment. We are also excited to report progress made with NT-I7 administration after CAR-T infusion, another important area of potential NT-I7 use.” NIT presentations at 2022 ASCO Annual Meeting: Primary Author Abstract Title Presentation details Naing, A Efficacy and Safety of NT-I7, Long-Acting Interleukin-7, plus Pembrolizumab in patients with advanced solid tumors: results from the Phase 2a study Abstract #2514 Poster discussion Session: Developmental Therapeutics -Immunotherapy June, 5 2022 11:30 AM-1:00 PM; 8:00 AM-11:00 AM CDT Gastman, B A phase 1b/2a study of safety and efficacy of NT-I7 in combination with anti- PD-L1 (atezolizumab) in patients with anti-PD-1/PD-L1 naïve or relapsed/refractory (R/R) high-risk skin cancers: The phase 1b report. Abstract #9561 Poster display Session: Melanoma/Skin Cancers June 6, 2022 1:15 PM-4:15 PM CDT Ghobadi, A Trial in Progress: A phase 1b study evaluating the safety, tolerability and preliminary anti-tumor activity of NT-I7 (efineptakin alfa), a long-acting human IL-7, post-tisagenlecleucel in subjects with relapsed/refractory large B-cell lymphoma Abstract # TPS7596 Poster display – Trial in progress (TiP) Poster Session: Hematologic Malignancies - Lymphoma and Chronic Lymphocytic Leukemia June 4, 2022 8:00 AM- 11:00 AM CDT Media inquiries : [email protected]

The release as fetched from its publisher. neoimmunetech.com ↗